Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.
Leukemic transformation (LT) from myelofibrosis has a very poor prognosis with the current treatment strategies. We hypothesized that allogeneic stem cell transplantation (ASCT) can improve outcomes for patients with LT, and reviewed 55 consecutive patients that were treated for myelofibrosis with ASCT at our institution. Fourteen patients (25%) were identified to have LT. Thirteen of these patients received induction chemotherapy and 6 achieved remission at the time of transplant. Conditioning regimen was melphalan (Mel)-based in 9 patients. All patients engrafted and achieved remission after transplant, whereas 4 subsequently relapsed. After a median follow-up of 31 months, 6 patients (49%) survived long term. Although limited by a small number of patients, this study suggests that patients with myelofibrosis and LT may achieve long-term remission after induction chemotherapy and ASCT.
Ciurea
Stefan O
SO
Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX, USA.
de Lima
Marcos
M
Giralt
Sergio
S
Saliba
Rima
R
Bueso-Ramos
Carlos
C
Andersson
Borje S
BS
Hosing
Chitra M
CM
Verstovsek
Srdan
S
Champlin
Richard E
RE
Popat
Uday
U
D000368:Aged; D002471:Cell Transformation, Neoplastic; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007938:Leukemia / Q000473:pathology / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D019172:Transplantation Conditioning; D016896:Treatment Outcome
D008558:Melphalan